**Abbreviations, acronyms & symbols**CO= Cardiac outputCVP= Central venous pressureMAP= Mean arterial pressureMB= Methylene blueMDA= MalondialdehydeNO= Nitric oxideNOx= Nitrite/nitratePAP= Pulmonary arterial pressurePCP= Pulmonary capillary pressurePVR= Pulmonary vascular resistanceSEM= Standard error of the meanSVR= Systemic vascular resistance

INTRODUCTION
============

Clinical and experimental observations prove that heparinneutralizing doses of protamine increase pulmonary artery pressures and decrease systemic blood pressure. Protamine also increases myocardial oxygen consumption, cardiac output (CO), and heart rate, and decreases systemic vascular resistance. These cardiovascular effects have clinical consequences that have justified studies in this area. Protamine adverse reactions usually can be classified into three different categories, namely: systemic hypotension, anaphylactoid reactions, and catastrophic pulmonary vasoconstriction. The precise mechanism that explains protamine-mediated systemic hypotension is unknown. Four experimental protocols performed at Mayo Clinic (Rochester, MN, USA) studied the intrinsic mechanism of protamine vasodilation. The first study reported *in vitro* systemic and coronary vasodilation after protamine infusion^\[[@r1]\]^. The second *in vitro* study suggested that pulmonary circulation is extensively involved in the protamine-mediated effects on endothelial function^\[[@r2]\]^. The third study, carried out in anesthetized dogs, reported the methylene blue (MB) and nitric oxide (NO) synthase blockers neutralization of the protamine vasodilatory effects^\[[@r3]\]^ The fourth study proposed that protamine also causes endothelium-dependent vasodilation in heart microvessels and conductance arteries by different mechanisms, including hyperpolarization^\[[@r4]\]^. Reviewing those experimental results and our clinical experience, we suggest MB as a novel approach to prevent and treat hemodynamic complications caused by the use of protamine after cardiopulmonary bypass^\[[@r5]\]^.

In the absence of prospective clinical trials and cumulative clinical evidence, based on the literature case reports, the present study was carried out to examine if MB can counteract or prevent protamine cardiovascular effects.

METHODS
=======

Experimental design
-------------------

The protocol included five heparinized pig groups: Group Sham - without any drug; Group MB - MB 3 mg/kg infusion; Group P - protamine; Group P/MB - MB after protamine; Group MB/P - MB before protamine. NO plasma levels were measured in each of the experimental groups. The procedures and handling of the animals were reviewed and approved by the Institutional Animal Care review board (Reg 142/2006).

Animal preparation and hemodynamic parameters
---------------------------------------------

Female Dalland pigs (22-26 kg) were induced to anesthesia with intramuscular administration of midazolam (15 mg/kg, Dormid^®^, Cristália Produtos Químicos Ltda., SP, Brazil) and tiletamine/zolazepam (10 mg/kg, Telazol^®^, Fort Dodge, IA, USA). Maintenance was achieved by total intravenous anesthesia using sufentanil (100 µg/h, Fastfan^®^, Cristália Produtos Químicos Ltda., SP, Brazil) and propofol (10 mg/kg/h, Propovan^®^, Cristália Produtos Químicos Ltda., SP, Brazil) delivered by syringe infusion pump (Syringe Infusion Pump, Harvard Apparatus, MA, USA). Pancuronium bromide (6 mg/h, Pancuron^®^, Cristália Produtos Químicos Ltda., SP, Brazil) was used as a muscle relaxant. Tracheostomy was performed on all animals immediately after induction of anesthesia. Volemia maintenance was achieved with intravenous infusion of sodium chloride 0.9% (5 mL/kg/h). A Swan-Ganz CCOmbo CCO/SvO~2~ 744HF75 (Edwards Lifesciences, CA, USA) catheter was placed in the right jugular vein and into the lumen of the main pulmonary artery. The left carotid artery was simultaneously catheterized. Mean arterial pressure (MAP), pulmonary arterial pressure (PAP), pulmonary capillary pressure (PCP) and central venous pressure (CVP) were recorded by the MP System 100 A (BioPac System, Inc., CA, USA). Cardiac output (CO), systemic vascular resistance (SVR) and pulmonary vascular resistance (PVR) were obtained by the Vigilance System (Edwards Lifesciences LLC, CA, USA). After instrumentation, a period of 20 minutes was allowed for anesthesia stabilization. After that, hemodynamic parameters and clinical conditions were recorded for 15 minutes.

Statistical analysis
--------------------

The hemodynamic results were expressed as mean ± standard error of the mean (SEM) and analysis of variance (Twoway ANOVA) and Bonferroni post-test. The Nitrite/Nitrate (NOx) and malondialdehyde (MDA) results were analyzed using paired T-test (Prism 5.0, GraphPad Software Inc., San Diego, CA, USA). Values are considered to be statistically significant at *P* values smaller than 0.05.

RESULTS
=======

Mean arterial pressure (MAP)
----------------------------

Groups Sham, MB and P showed unchanged parameters. Intravenous P infusion caused MAP drop followed by a recovery trend after 25-30 minutes. The MAP curves of Sham, P and MB were not different and the effect was considered not quite significant (*P*=0.05) ([Figure 1A](#f1){ref-type="fig"}).

Fig. 1Mean arterial pressure (n=6, Two-way ANOVA. Bonferroni post-test. P\<0.05). MAP=mean arterial pressure; MB=methylene blue; P=protamine

In the MB infusion before protamine group (Group MB/P), the drop in MAP was less severe, with rapid recovery. In MB infusion after protamine group (Group P/MB), marked MAP decrease after protamine was observed, with recovery after MB injection. The curves of P, P/MB and MB/P groups were not different and the effect was not significant (*P*=0.3786) ([Figure 1B](#f1){ref-type="fig"}).

Cardiac output (CO)
-------------------

Groups Sham, P and MB showed unchanged parameters (n=6; *P*\>0.05). The statistical significance was borderline and the software pointed out that a larger number of animals would improve the data. In Group P, CO decreased and remained stable until the end of the protamine injection ([Figure 2A](#f2){ref-type="fig"}).

Fig. 2Cardiac output (n=6, Two-way ANOVA. Bonferroni post-test. P\<.05). CO=cardiac output; MB=methylene blue; P=protamine

In Group P/MB, CO decreased after protamine infusion, recovering after MB infusion. In the Protamine after MB group, there was a progressive CO increase to the time of protamine injection, when CO decreased. In addition, the curves of *P*, P/MB and MB/P were different and presented statistical difference (*P*\<0.05) between groups P and MB/P at 30 minutes ([Figure 2B](#f2){ref-type="fig"}).

Systemic vascular resistance (SVR)
----------------------------------

Groups Sham and MB showed unchanged parameters. Group P sustained an SVR increase until the end of the protamine injection. The SVR curves of Sham, P and MB were different and presented statistical difference (*P*\<0.01) between groups P and Sham at 35 and 40 minutes ([Figure 3A](#f3){ref-type="fig"}).

Fig. 3Systemic vascular resistance (n=6, Two-way ANOVA. Bonferroni post-test. P\<0.05). SVR=systemic vascular resistance; MB=methylene blue; P=protamine

Group P/MB sustained SVR increase after P and MB injections and in Group MB/P, the SVR dropped after protamine followed by immediate SVR increase. Moreover, there was statistical difference (*P*\<0.05) between group P *versus* P/MB and P *versus* MB/P at 40 minutes ([Figure 3B](#f3){ref-type="fig"}).

Pulmonary arterial pressure (PAP)
---------------------------------

The PAP curves in the Sham, P and MB groups showed a statistically significant increase (*P*\<0.001) after protamine injection (15 minutes), followed by immediate decrease ([Figure 4A](#f4){ref-type="fig"}). Also, the curves of Groups P, P/MB and MB/P showed statistically significant difference (*P*\<0.01) between Group P versus P/MB and P *versus* MB/P at 15 minutes ([Figure 4B](#f4){ref-type="fig"}).

Fig. 4Pulmonary arterial pressure (n=6, Two-way ANOVA. Bonferroni post-test. P\<0.05). PAP=pulmonary artery pressure; MB=methylene blue; P=protamine

Central venous pressure (CVP)
-----------------------------

The CVP curves of Sham and MB remained stable during 40 minutes of experiment. On the other hand, Group P presented an increase at minute 15, followed by immediate decrease ([Figure 5A](#f5){ref-type="fig"}). The curve in the MB/P group remained stable during 40 minutes of experiment and, P and P/MB presented an increase at minute 15, followed by immediate decrease ([Figure 5B](#f5){ref-type="fig"}).

Fig. 5Central venous pressure (n=6, Two-way ANOVA. Bonferroni post-test. P\<0.05). CVP=central venous pressure; MB=methylene blue; P=protamine

Plasma nitrite/nitrate (NOx)
----------------------------

Plasma NOx concentrations did not present statistically significant difference ([Figure 6](#f6){ref-type="fig"}).

Fig. 6Plasma Nitrite/Nitrate (NOx) concentrations (n=6; t test. P\<0.05).

Malondialdehyde (MDA)
---------------------

MDA concentrations did not present statistically significant difference ([Figure 7](#f7){ref-type="fig"}).

Fig. 7Malondialdehyde concentrations (n = 6; t test. P\<0.05).

DISCUSSION
==========

Heparin/protamine interaction is a topic of interest due to its use during cardiopulmonary bypass. These drugs are prescribed to more than 2,000,000 patients every year. From clinical and experimental data, heparin-neutralizing doses of protamine increase pulmonary artery pressures and decrease systemic blood pressure, myocardial oxygen consumption, CO, heart rate, and SVR. Those cardiovascular effects have clinical consequences that justified studies in this area.

Transitory hypotension in animals after protamine infusion has been observed as an experimental effect for \> 50 years^\[[@r6]-[@r8]\]^. However, until the development of cardiac surgery, protamineinduced hypotension was an experimental finding of little clinical relevance. As protamine became largely used in clinical and surgical procedures, its reactions frequently led to severe systemic hypotension, pulmonary hypertension, and shock^\[[@r9]-[@r13]\]^. Those consequences can be potentially dangerous, especially immediately after cardiopulmonary bypass, when intravascular volumes are not constant and cardiac function may be impaired.

Protamine can also cause hemodynamic disturbance by means of anaphylactic reactions^\[[@r6],[@r14],[@r15]\]^. Indeed, Horrow^\[[@r15]\]^ classified protamine adverse reactions in three different categories: systemic hypotension, anaphylactoid reactions, and catastrophic pulmonary vasoconstriction.

The precise mechanism that explains protamine-mediated systemic hypotension is unknown. However, it is suggested that protamine decreases peripheral vascular resistance rather than depressing myocardial function^\[[@r9],[@r11],[@r16],[@r17]\]^. Protamine sulfate (either as a free drug or complexed with heparin) binds to an unidentified endothelial cell receptor that mediates the conversion of L-arginine to NO. NO released abluminally activates soluble guanylate cyclase in the vascular smooth muscle to induce cyclic GMP (cGMP)-mediated relaxation (vasodilation). This results in a decrease in peripheral vascular resistance and hypotension. NO released luminally would promote thrombolysis and inhibit platelet adhesion in the blood vessel^\[[@r1]\]^. Against this hypothesis, it is important to report that Castresana et al.^\[[@r17]\]^, using pig vascular smooth muscle cell culture experiments, showed that protamine does not alter the responses of the intracellular second messengers, cGMP and cAMP, to the vasodilators sodium nitroprusside, atrial natriuretic peptide, isoproterenol, and forskolin. Those results do not support the hypothesis that protamine sensitizes vascular smooth muscle cells to the NO/endothelium-derived relaxing factor. Favorable to the NO/endothelium-dependent mechanism, MB has been successfully used to reverse protamine vasoplegic reactions in humans^\[[@r18]-[@r20]\]^.

For the endothelium-dependent vasodilatation in the pulmonary artery, a proposed mechanism suggests that protamine sulfate binds to an unidentified endothelial cell receptor to induce NO production from the amino acid L-arginine. NO then diffuses to the underlying vascular smooth muscle to induce relaxation (vasodilatation). NO released into the lumen would promote thombrolysis and inhibit platelet adhesion in the blood vessel. The conversion of L-arginine to NO can be inhibited by NG-monomethyl-L-arginine (L-NMMA), a methylated form of L-arginine. In addition, differently from the systemic circulation, heparin can inhibit the ability of protamine to induce NO, presumably by preventing the binding of protamine to receptor^\[[@r2]\]^. Favorable to this hypothesis is the use of inhaled NO to control pulmonary hypertension^\[[@r21]-[@r23]\]^.

Plasma NOx and indirect free radical activity estimated by measuring MDA levels surprisingly did not show differences. Probably, the experimental time (40 minutes) was not enough for the laboratory techniques to detect the possible stimulus for NO release and free radical (lipidperoxidation) activity.

In conclusion, based on the results described, the following can be stated: 1) Individual MB infusion did not change MAP, CO and SVR values whereas MB injected before protamine attenuated the hypotension with rapid recovery and when injected after protamine, it reversed the marked hypotension; 2) CO decreased after protamine infusion, recovering after post-MB infusion, and MB infusion before protamine caused a progressive CO increase, followed by attenuation at the time of protamine injection; and 3) There was sustained SVR increase until the end of protamine injection, decreased SVR after protamine, followed by immediate SVR increase when MB was injected before protamine, and sustained SVR increase after protamine and post MB injections. Reviewing these experimental results and our clinical experience, we suggest that MB prevents and treats hemodynamic protamine complications.

Study limitations. It is mandatory to emphasize that the animals were not under cardiopulmonary bypass that causes systemic inflammatory reaction, since this reaction should exacerbate the hemodynamic effects of protamine. Other relevant limitation is the number of animals used for each group (n=6), except for borderline statistical significances, the statistical software pointed out that a larger number of animals would improve the data.
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